Clinical experience in the neoadjuvant treatment of unresectable differentiated thyroid cancer with the lenvatinib

Introduction. In some cases of differentiated thyroid cancer expansion into the main vessels and adjacent organs, surgical intervention is impossible. Not many cases of successful use of targeted therapy as neoadjuvant regimen to treat nonresectable differentiated thyroid cancer were reported, but this approach can be an option in management of such patients.

Aim. To analyze clinical experience of using lenvatinib as neoadjuvant therapy in patients with primary nonresectable differentiated thyroid cancer.

Materials and methods. Retrospective analysis of treatment of 7 patients with primary nonresectable differentiated thyroid cancer with lenvatinib as neoadjuvant therapy at Chelyabinsk Regional Clinical Center for Oncology and Nuclear medicine between 2021 and 2023 was performed.

Results. Treatment response was evaluated in 4 (71.4 %) patients. In 2 (50 %) patients, partial response was observed, in 2 - stable disease. Radical surgical intervention became possible in 2 patients. The other 2 patients could not undergo surgery: in 1 patients time to progression was 17.8 months, therapy was changed to the 2nd line drug cabozantinib; 1 female patient with best response (partial) currently continues lenvatinib treatment, tumor is nonresectable, duration of drug administration is 8.9 months.

Conclusion. Our experience of using lenvatinib in patients with nonresectable differentiated thyroid cancer shows that this therapy can be successfully used as neoadjuvant treatment in this patient group.

1. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97(5):418-28. DOI: 10.1016/0002-9343(94)90321-2

2. Ark N., Zemo S., Nolen D. et al. Management of locally invasive well-differentiated thyroid cancer. Surg Oncol Clin 2008;17(1): 145-55. DOI: 10.1016/j.soc.2007.10.009

3. Bolotina L.V., Vladimirova L.Yu., Dengina N.V. et al. Practical recommendations for the drug treatment of tumors of the head and neck. Practical recommendations of RUSSCO. Zlokachestvennye opuholi = Malignant Tumors 2023;13:113. (In Russ.). DOI: 10.18027/2224-5057-2023-13-3s2-1-100-119

4. Isaev P.A., Vasilkov S.V., Pimonova I.S. et al. Neoadjuvant targeted therapy for differentiated thyroid cancer (clinical observation). Opukholi golovy i shei = Head and Neck Tumors 2017;7(1):86-90. (In Russ.). DOI: 10.17650/2222-1468-2017-7-1-86-90

5. Tsuboi M., Takizawa H., Aoyama M., Tangoku A. Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report. Int J Surg Case Rep 2017;41:89-92. DOI: 10.1016/j.ijscr.2017.10.010

6. Matsui J., Funahashi Y., Uenaka T. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17):5459-65. DOI: 10.1158/1078-0432.CCR-07-5270